The role of targeted therapy in non-small cell lung cancer

Critical Reviews in Oncology/Hematology

Volumn 51, Issue 1, 2004, Pages 29-44

  Maione, Paolo ^a   Rossi, Antonio ^a   Airoma, Giuseppe ^a   Ferrara, Carmine ^a   Castaldo, Vincenzo ^a   Gridelli, Cesare ^a  

^a S G MOSCATI HOSPITAL   (Italy)

Author keywords

Gefitinib; New biological agents; Non small cell lung cancer; Targeted therapy

Indexed keywords

2 [2 PROPYL 3 [3 [2 ETHYL 4 (4 FLUOROPHENYL) 5 HYDROXYPHENOXY]PROPOXY]PHENOXY]BENZOIC ACID; 3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; AE 941; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CANERTINIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; GEFITINIB; GEMCITABINE; GSK 249553; ISIS 3521; LAPATINIB; LONAFARNIB; OBLIMERSEN; PACLITAXEL; PELITINIB; PROTEIN KINASE C INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; REBIMASTAT; SEMAXANIB; SRL 172; TIPIFARNIB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; ZD 2171;

ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DIARRHEA; DISEASE ASSOCIATION; DISEASE COURSE; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; FATIGUE; FEVER; FLUSHING; GASTROINTESTINAL TOXICITY; GENE OVEREXPRESSION; HEADACHE; HEART INFARCTION; HEMOPTYSIS; HUMAN; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; NAUSEA; NEUTROPENIA; PAIN; RASH; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; DRUG DELIVERY SYSTEMS; GENE THERAPY; HUMANS; IMMUNOTHERAPY, ACTIVE; LUNG NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION;

EID: 2942635060     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2004.02.002     Document Type: Review

References (137)

1. Jemal A., Murray T., Samuels A., et al. Cancer Statistics, 2002. CA Cancer J. Clin. 53:2003;5-26
2. Parkin D.M., Bray F., Ferlay J., et al. Estimating the world cancer burden: Globocan 2000. Int. J. Cancer. 94:2001;153-156
3. Bunn PA. Novel targeted agents for the treatment of lung cancer. American Society of Clinical Oncology 2002 Educational Book. p. 683-92.
4. Dy G.K., Adjei A.A. Novel targets for lung cancer therapy: part I. J. Clin. Oncol. 20:2002;2881-2894
5. Dy G.K., Adjei A.A. Novel targets for lung cancer therapy: part II. J. Clin. Oncol. 20:2002;3016-3028
6. Eckardt SG, Eisenhauer E, Parulekar WR, Pazdur R, Hirschfeld S. Developmental therapeutics: successes and failures of clinical trial designs of targeted compounds. American Society of Clinical Oncology 2003 Educational Book. p. 209-19.
7. Korn E.L., Arbuck S.G., Pluda J.M., Simon R., Kaplan R.S., Christian M.C. Clinical trial designs for cytostatic agents: are new approaches needed? J. Clin. Oncol. 19:2001;265-272
8. Salomon D.S., Brandt R., Ciardiello F., Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Haematol. 19:1995;183-232
9. Ciardiello F., Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin. Cancer Res. 7:2001;2958-2970
10. Rusch V., Klimstra D., Venkatraman E., et al. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin. Cancer Res. 3:1997;515-522
11. Fontanini G., De Laurentiis M., Vignati S., et al. Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. Clin. Cancer Res. 4:1998;241-249
12. Rusch V., Baselga J., Cordon-Cardo C., et al. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res. 53:1993;2379-2385
13. Selvaggi G., Scagliotti G.V., Novello S., et al. Prospective evaluation of epidermal growth factor (EGFR) expression in completely resected non-small cell lung cancer (NSCLC): effects of EGFR on long-term follow-up. Proc. Am. Soc. Clin. Oncol. 21:2002;337a
14. Ciardiello F., Bianco R., Damiano V., et al. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin. Cancer Res. 5:1999;909-916
15. Falcey J., Pfister D., Cohen R., et al. A study of anti-epidermal growth factor receptor (EGFr) monoclonal antibody C225 and cisplatin in patients with head and neck or lung carcinomas. Proc. Am. Soc. Clin. Oncol. 16:1997;383a
16. Cunningham D., Humblet Y., Siena S., et al. Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC). Proc. Am. Soc. Clin. Oncol. 22:2003;252
17. Baselga J., Trigo J.M., Bourhis J., et al. Cetuximab (C225) plus cisplatin/carboplatin is active in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) progressing on a same dose and schedule platinum-based regimen. Proc. Am. Soc. Clin. Oncol. 21:2002;633. [abstract]
18. Kelly K., Hanna N., Rosemberg A., Bunn P.A., Needle M.N. A multi-centered phase I/II study of cetuximab in combination with paclitaxel and carboplatin in untreated non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 22:2003;644
19. Robert F., Blumenschein G., Dicke K., Tseng J., Saleh M.N., Needle M. Phase Ib/IIa study of anti-epidermal growth factor receptor (EGFR) antibody, cetuximab, in combination with gemcitabine/carboplatin in patients with advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 22:2003;643
20. Kim E.S., Mauer A.M., Tran H.A.T., et al. A phase II study of cetuximab, an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer: final report. Proc. Am. Soc. Clin. Oncol. 22:2003;642
21. Yang X.D., Jia X.C., Corvalan J.R., et al. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody for cancer therapy. Crit. Rev. Oncol. Hematol. 38:2001;17-23
22. Wakeling A.E., Guy S.P., Woodburn J.R., Ashton S.E., Curry B.J., Barker A.J., et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res. 62:2002;5749-5754
23. Herbst R.S., Maddox A.M., Rothenberg M.L., et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J. Clin. Oncol. 20:2002;3815-3825
24. Giaccone G., Johnson D.H., Manegold C., et al. A phase III clinical trial of ZD1839 (Iressa) in combination with gemcitabine and cisplatin in chemotherapy-naïve patients with advanced non-small cell lung cancer (INTACT 1). Ann. Oncol. 13:2002;2
25. Johnson D.H., Herbst R., Giaccone G., et al. ZD1839 (Iressa) in combination with paclitaxel, ZD1839 (Iressa) in combination with paclitaxel & carboplatin in chemotherapy-naïve patients with advanced non-small cell lung cancer (NSCLC): results from a phase III clinical trial (INTACT 2). Ann. Oncol. 13:2002;127
26. Fukuoka M., Yano S., Giaccone G., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 21:2003;2237-2246
27. Kris M.G., Natale B.R., Herbst R.S., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 290(16):2003;2149-2158
28. Pallis A.G., Mavroudis D., Androulakis N., et al. ZD1839, a novel, oral epidermal growth factor receptor-tyrosine kinase inhibitor, as salvage treatment in patients with advanced non-small cell lung cancer. Experience from a single center participating in a compassionate use program. Lung Cancer. 40:2003;301-307
29. Santoro A., Cavina R., Latteri F., et al. Activity of a specific inhibitor, gefitinib (Iressa(TM), ZD1839), of epidermal growth factor receptor in refractory non-small-cell lung cancer. Ann. Oncol. 15:2004;33-37
30. Cappuzzo F., Ardizzoni A., Soto-Parra H., et al. Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer. Lung Cancer. 41:2003;227-231
31. Villano J.L., Mauer A.M., Vokes E.E. A case study documenting the anticancer activity of ZD1839 (Iressa) in the brain. Ann. Oncol. 14:2003;656-657
32. Wu Y.L., Yang X.N., Gu L.J. The characteristics of patients with non-small cell lung cancer with complete response treated with ZD1839. Proc. Am. Soc. Clin. Oncol. 22:2003;689
33. Wong N.S., Lim S.T., Lim W.T., Leong S.S., Tan E.H. ZD1839 is more effective in patients with non-small cell lung cancer (NSCLC) who were lifetime non-tobacco users. Proc. Am. Soc. Clin. Oncol. 22:2003;694
34. Shah N.T., Miller V.A., Kris M.G., et al. Bronchioalveolar histology and smoking history predict response to gefitinib. Proc. Am. Soc. Clin. Oncol. 22:2003;628
35. Herbst R.S., Giaccone G., Schiller J., et al. Subset analyses of INTACT results for gefitinib (ZD1839) when combined with platinum-based chemotherapy (CT) for advanced non-small-cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 22:2003;627
36. Fandi A., Gatzemeier U., Smith R., Averbuch S., Manegold C. Final data from a pilot trial of gefitinib (ZD1839) in combination with docetaxel in patients with advanced or metastatic non-small-cell lung cancer (NSCLC): safety and pharmacokinetics. Proc. Am. Soc. Clin. Oncol. 22:2003;655
37. Copin M., Kommareddy A., Behnken D., et al. Gefitinib in elderly patients with non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 22:2003;758
38. Gridelli C., Maione P., Castaldo V., Rossi A. Gefitinib in elderly and unfit patients affected by advanced non-small cell lung cancer. Br. J. Cancer. 89:2003;1827-1829
39. Soto Parra H., Cavina R., Zucali P., et al. Gefitinib in elderly patients with progressive, pretreated, no small cell lung cancer: results from the Istituto Clinico Humanitas. Br. J. Cancer. 89(Suppl. 2):2003;S25-S35
40. Cappuzzo F., Bartolini S., Ceresoli G.L., et al. Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC). Br. J. Cancer. 90:2004;82-86
41. Stahel R., Rossi A., Petruzelka L., et al. Lessons from the "Iressa" Expanded Access Programme: gefitinib in special non-small-cell lung cancer patient populations. Br. J. Cancer. 89(Suppl. 2):2003;S19-S23
42. Hidalgo M., Siu L.L., Neumanitis K., et al. Phase I and pharmacology study of OSI-774, and epidermal growth factor receptor tyrosine kinase inhibitor in patients with advanced solid malignancies. J. Clin. Oncol. 119:2001;3267-3279
43. Perez-Soler R., Chachoua A., Huberman M., et al. A phase II trial of the epidermal growth factor tyrosine kinase inhibitor OSI-774 following platinum-based chemotherapy in patients with advanced, EGFR-expressing, non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 20:2001;310a
44. Clark G.M., Perez-Soler R., Siu L., Gordon A., Santabarbara P. Rash severity is predictive of increased survival with erlotinib Hclas. Proc. Am. Soc. Clin. Oncol. 22:2003;196
45. Soulieres D., Senzer N.N., Vokes E.E., et al. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J. Clin. Oncol. 22:2004;77-85
46. Miller V.A., Patel J., Shah N., et al. The epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) shows promising activity in patients with bronchioloalveolar cell carcinoma (BAC): preliminary results of a phase II trial. Proc. Am. Soc. Clin. Oncol. 22:2003;619
47. Garrison M.A., Tolcher A., McGreery H., et al. A phase I pharmacokinetic study of CI-1033, a pan-erbB tyrosine kinase inhibitor, given orally on days 1, 8 and 15 every 28 days to patients with solid tumors. Proc. Am. Soc. Clin. Oncol. 21:2001;72a
48. Shin D.M., Nemunaitis J., Zinner R.G., et al. A phase I clinical and biomarker study of CI-1033, a novel pan-ErbB tyrosine kinase inhibitor in patients with solid tumors. Proc. Am. Soc. Clin. Oncol. 20:2001;82a
49. Zinner R.G., Donato N.J., Neumanitis J., et al. Biomarker modulation in tumor and skin biopsy samples from patients with solid tumors following treatment with the pan-erbB tyrosine kinase inhibitor, CI-1033. Proc. Am. Soc. Clin. Oncol. 21:2002;15a
50. Dumez H., Hoekstra R., Eskens F., et al. A phase I and pharmacologic study of PKI 166, and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, administered orally 3 times a week to patients with advanced cancer. Proc. Am. Soc. Clin. Oncol. 21:2002;86a
51. De Simone P.A., Bence A.K., Anderson E.B., et al. A phase I study to investigate the safety, tolerability, and pharmacokinetics of single oral escalating doses of GW572016 in healthy volunteers. Proc. Am. Soc. Clin. Oncol. 21:2002;94a
52. Hidalgo M., Erlichman C., Rawinsky E.K., et al. Phase I trial of EKB-569, an irreversible inhibitor of the epidermal growth factor (EGFR) in patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol. 21:2002;17a
53. Hirsch F.R., Varella-Garcia M., Franklin W.A., et al. Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas. Br. J. Cancer. 86:2002;1449-1456
54. Kern J.A., Swartz D.A., Nordberg J.E., et al. P185-neu expression in human lung adenocarcinoma predicts shortened survival. Cancer Res. 50:1990;5184-5191
55. Tsai C.M., Chang K.T., Wu L.H., et al. Correlation between intrinsic chemoresistance and HER-2/neu gene expression, p53 gene mutations, and cell proliferation characteristics in NSCLC cell lines. Cancer Res. 56:1996;206-209
56. Pfeiffer P., Clausen P.P., Andersen K., et al. Lack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185HER-2 in patients with systematically untreated non-small-cell lung cancer. An immunohistochemical study cryosections. Br. J. Cancer. 74:1996;86-91
57. Hirsch F.R., Varella-Garcia M., Franklin W.A., et al. Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas. Br. J. Cancer. 86:2002;1449-1456
58. Bunn P.A., Helfrich B., Soriano A.F., et al. Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents. Clin. Cancer Res. 7:2001;3239-3250
59. Cox G., Vyberg M., Melgaard B., Askaa J., Oster A., O'Byrne K.J. Herceptest: HER2 expression and gene amplification in non-small cell lung cancer. Int. J. Cancer. 92:2001;480-483
60. Lewis G.D., Figari I., Fendly B., et al. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol. Immunother. 37:1993;255-263
61. Langer C.J., Adak S., Thor A., Vangel M., Johnson D. Phase II eastern cooperative oncology group (ECOG) pilot study of paclitaxel (P), carboplatin (C), and trastuzumab (T) in HER-2/neu (+) advanced non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 20:2001;315a
62. Krug L.M., Miller V.A., Crapanzano J., et al. Randomized phase II trial of trastuzumab (Tras) plus either weekly docetaxel (Dopc) or paclitaxel (Pac) in previously untreated advanced non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 20:2001;333a
63. Zinner G.R., Glisson B.S., Pisters K.M., et al. Cisplatin and gemcitabine combined with herceptin in patients (pts) with HER2 overexpressing, untreated, advanced, non-small-cell lung cancer (NSCLC): a phase II trial. Proc. Am. Soc. Clin. Oncol. 20:2001;328a
64. Gatzemeier U., Groth G., Butts C., et al. Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann. Oncol. 15:2004;19-27
65. Folkman J. What is the evidence that tumors are angiogenesis dependent? J. Natl. Canc. Inst. 82:1990;4-6
66. Keshet E., Ben-Sasson S.A. Anticancer drug targets: approaching angiogenesis. J. Clin. Invest. 104:1999;1497-1501
67. Ferrera N. Vascular endothelial growth factor. Trends Cardiovasc. Med. 3:1993;244-250
68. Millauer B., Longhi M.P., Plate K.H., et al. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res. 56:1996;1615-1620
69. DeVore R.F., Fehrenbacher L., Herbst R.S., et al. A randomized phase II trial comparing rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIB/IV NSCLC. Proc. Am. Soc. Clin. Oncol. 19:2000;1896
70. Johnson D.H., DeVore R., Kabbinavar F., Herbst R., Holmgren E., Novotny W. Carboplatin (C) + paclitaxel (T) + rhuMAb-VEGF (AVF) may prolong survival in advanced non-squamous lung cancer. Proc. Am. Soc. Clin. Oncol. 20:2001;315a
71. Rosen L., Mulay M., Mayers A., et al. Phase I dose-escalating trial of SU5416, a novel angiogenesis inhibitor in patients with advanced malignancies. Proc. Am. Soc. Clin. Oncol. 18:1999;161a
72. Kuenen B.C., Rosen L., Smit E.F., et al. Dose-finding and pharmacokinetic study of cisplatin. J. Clin. Oncol. 20:2002;1657-1667
73. Wedge S.R., Ogilvie D.J., Dukes M. Chronic and acute effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, on established human tumour xenografts. Proc. Am. Assoc. Cancer Res. 41:2000;3610
74. Wedge S.R., Ogilvie D.J., Dukes M., et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res. 62:2002;4645-4655
75. Basser R., Hurwitz H., Barge A., et al. Phase I pharmacokinetic and biological study of the angiogenesis inhibitor, ZD6474, in patients with solid tumors. Proc. Am. Soc. Clin. Oncol. 20:2001;100a
76. Smylie M., Mercier R., Aboulafia D., et al. Phase III study of the matrix metalloproteinase (MMP) inhibitor Prinomastat in patients having advanced non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 20:2001;307a
77. Gupta E., Huang M., Mao Y., et al. Pharmacokinetic (PK) evaluation of BMS-275291, a matrix metalloproteinase (MMP) inhibitor, in cancer patients. Proc. Am. Soc. Clin. Oncol. 20:2001;76a
78. Latreille J., Batist G., Laberge F., et al. Phase I/II trial of the safety and efficacy of AE-941 (Neovastat) in the treatment of non-small-cell lung cancer. Clin. Lung Cancer. 4:2003;231-236
79. Nishizuka Y. The molecular heterogeneity of protein kinase C and its implications for cellular regulation. Nature. 334:1988;661-665
80. Tamaoki T., Nakano H. Potent and specific inhibitors of protein kinase C of microbial origin. Biotechnology. 8:1990;732-735
81. Nemunaitis J., Holmlund J.T., Kraynak M., et al. Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer. J. Clin. Oncol. 17:1999;3586-3595
82. Jansen B., Zangemeister-Wittke U. Antisense therapy for cancer - the time of truth. Lancet Oncol. 3:2002;672-683
83. Yuen A., Halsey J., Fisher G., et al. Phase I/II trial of ISIS 3521, an antisense inhibitor of PKC-alpha, with carboplatin and paclitaxel in non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 20:2001;309a
84. Lynch T.J., Raju R., Lind M., et al. Randomized phase III trial of chemotherapy and antisense oligonucleotide LY900003 (ISIS 3521) in patients with advanced NSCLC: initial report. Proc. Am. Soc. Clin. Oncol. 22:2003;623
85. Rowinsky E.K., Windle J.J., Von Hoff D. Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development. J. Clin. Oncol. 17:1999;3631-3652
86. Adjei A.A. Blocking oncogenic ras signaling for cancer therapy. J. Natl. Cancer Inst. 93:2001;1062-1074
87. Dang T., Johnson D.H., Kelly K., Rizvi N., Holmlund J., Dorr A. Multicenter phase II trial of an antisense inhibitor of H-ras (ISIS 3503) in advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 20:2001;332a
88. Piccart-Gebhart M.J., Branle F., de Valeriola D., et al. Phase I., clinical and pharmacokinetic (PK) trial of the farnesyl transferase inhibitor (FTI) R115777 + docetaxel: a promising combination in patients (PTS) with solid tumors. Proc. Am. Soc. Clin. Oncol. 20:2001;80a
89. Adjei A.A., Mauer A., Bruzek L., et al. Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 21:2003;1760-1766
90. Adjei A.A., Erlichman C., Davis J.N., et al. A phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity. Cancer Res. 60:2000;1871-1877
91. Khuri F.R., Glisson B.S., Meyers M.L., et al. Phase I study of farnesyl transferase inhibitor (FTI) SCH66336 with paclitaxel in solid tumors: dose finding, pharmacokinetics, efficacy/safety. Proc. Am. Soc. Clin. Oncol. 19:2000;205a
92. Kim E.S., Kies M.S., Fossella F.V., et al. A phase I/II study of the farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) with paclitaxel in taxane-refractory/resistant patients with non-small cell lung cancer (NSCLC): final report. Proc. Annu. Meet. Am. Assoc. Cancer Res. 43:2002;2735. [abstract]
93. Rose W.C., Lee F.Y.F., Fairchild C.R., et al. Preclinical antitumor activity of BMS-214662, a highly apoptotic and novel farnesyltransferase inhibitor. Cancer Res. 61:2001;7507-7517
94. Dy G.K., Bruzek L.M., Croghan G.A., et al. A phase I trial of the novel farnesyl protein transferase inhibitor, BMS-214662, in combination with paclitaxel and carboplatin in patients with advanced cancer. Proc. Annu. Meet. Am. Assoc. Cancer Res. 43:2002;2735. [abstract]
95. Reed J.C., Miyashita T., Takayama S., et al. Bcl-2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J. Cell Biochem. 60:1996;23-32
96. Berardo M.D., Elledge R.M., Moor C., Clark G.M., Osborne C.K., Allred D.C. Bcl-2 and apoptosis in lymph node positive breast carcinoma. Cancer. 82:1998;1296-1302
97. Reed J.C. Mechanisms of apoptosis avoidance in cancer. Curr. Opin. Oncol. 11:1999;68-75
98. Zangemeister-Wittke U., Schenker T., Luedke G.H., Stahel R.A. Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines. Br. J. Cancer. 78:1998;1035-1042
99. Soslow R.A., Dannenberg J.A., Rush D., et al. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer. 89:2000;2637-2645
100. DuBois R.N., Smalley W.E. Cyclooxygenase, NSAIDs, and colorectal cancer. J. Gastroenterol. 31:1996;898-906
101. Fosslien E. Molecular pathology of cyclooxygenase-2 in neoplasia. Ann. Clin. Lab. Sci. 30:2000;3-21
102. Kelley D.J., Mestre J.R., Subbaramaiah K., et al. Benzo[a]pyrene up-regulates cyclooxygenase-2 gene expression in oral epithelial cells. Carcinogenesis. 18:1997;795-799
103. Wolff H., Saukkonen K., Anttila S., Karjalainen A., Vainio H., Ristimaki A. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res. 58:1998;4997-5001
104. Hida T., Leyton J., Makheja A.N., et al. Non-small cell lung cancer cycloxygenase activity and proliferation are inhibited by non-steroidal antiinflammatory drugs. Anticancer Res. 18:1998;775-782
105. Sanchez-Alcazar J.A., Bradbury D.A., Pang L., Knox A.J. Cyclooxygenase (COX) inhibitors induce apoptosis in non-small cell lung cancer through cyclooxygenase independent pathways. Lung Cancer. 40:2003;33-44
106. Hanif R., Pittas A., Feng Y., et al. Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem. Pharmacol. 52:1996;237-245
107. Hida T., Yatabe Y., Achiwa H., et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res. 58:1998;3761-3764
108. Hida T., Kozaki K., Muramatsu H., et al. Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin. Cancer Res. 6:2000;2006-2011
109. Pyo H., Choy H., Amorino G.P., et al. A selective cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2. Clin. Cancer Res. 7:2001;2998-3005
110. Johnson D.H., Csiki I., Gonzalez A., et al. Cyclooxygenase-2 (COX-2) inhibition in non-small cell lung cancer (NSCLC): preliminary results of a phase II trial. Proc. Am. Soc. Clin. Oncol. 22:2003;640
111. Gadgeel SM, Thatai, Kraut M. Phase II study of celecoxib and docetaxel in non-small cell lung cancer (NSCLC) patients with progression after platinum-based therapy. Proc Am Soc Clin Oncol 2003;22:684.
112. Altorki N.K., Keresztes R.S., Port J.L., et al. Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. J. Clin. Oncol. 21:2003;2645-2650
113. Avis I.M., Jett M., Boyle T., et al. Growth control of lung cancer by interruption of 5-lipoxygenase-mediated growth factor signaling. J. Clin. Invest. 97:1996;806-813
114. Rioux N., Castonguay A. Inhibitors of lipoxygenase: a new class of cancer chemopreventive agents. Carcinogenesis. 19:1998;1393-1400
115. Hege K.M., Carbone D.P. Lung cancer vaccines and gene therapy. Lung Cancer. 41:2003;S103-S113
116. Salgia R., Lynch T., Skarin A., et al. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony stimulating factor augments anti-tumor immunity in patients with metastatic non-small cell lung carcinoma. J. Clin. Oncol. 21:2003;624-630
117. Nemunaitis J., Sterman D., Jablons D., et al. A phase I/II study of autologous GM-CSF gene-modified cancer vaccines in subjects with non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 20:2001;255a
118. Palmer M., Parker J., Modi S., et al. Phase I study of the BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small-cell lung cancer. Clin. Lung Cancer. 3:2001;49-57
119. Gotoh K., Yatabe Y., Sugiura T., et al. Frequency of MAGE-3 gene expression in HLA-A2 positive patients with non-small cell lung cancer. Lung Cancer. 20:1998;117-125
120. O'Brien M.E., Saini A., Smith I.E., et al. A randomized phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma. Br. J. Cancer. 83:2000;853-857
121. O'Brien M.E., Anderson H., Kaukei E., O'Byrne K., Pawlicki M., von Pawel J., et al. Improved quality of life with the addition of SRL 172 (killed Mycobacterium vaccae) to standard chemotherapy in patients with advanced non-small cell lung cancer: phase III results. Lung Cancer. 41(Suppl. 2):2003;S35. [abstract O-109]
122. Fujiwara T., Cai D., Georges R., et al. Therapeutical effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model. J. Natl. Cancer Inst. 86:1994;1458-1462
123. Zhang W., Fang X., Mazur W., et al. High-efficiency gene transfer and high level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus. Cancer Gene Ther. 1:1994;5-13
124. Swisher S., Roth J., Nemunaitis J., et al. Adenovirus-mediated p53 gene transfer in advanced non-small cell lung cancer. J. Natl. Cancer Inst. 91:1999;763-771
125. Kubba S., Adak S., Schiller J. Phase I trial of adenovirus p53 in bronchioloalveolar cell lung carcinoma (BAC) administered by bronchoalveolar lavage. Proc. Am. Soc. Clin. Oncol. 19:2000;487a
126. Nemunaitis J., Swisher S., Timmons S., et al. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J. Clin. Oncol. 18:2000;609-622
127. Schuler M., Herrmann R., DeGreve J., et al. Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small cell lung cancer results of a multicenter phase II study. J. Clin. Oncol. 19:2001;1750-1758
128. Swisher S., Roth J., Komaki K., et al. A phase II trial of adenoviral mediated p53 gene transfer (RPR/INGN 201) in conjunction with radiation therapy in patients with localized non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 19:2000;461a
129. Hwang H., Smythe W., Elshami A., et al. Gene therapy using adenovirus carrying the herpes simplex thymidine kinase gene to treat in vitro models of human malignant mesothelioma and lung cancer. Am. J. Resp. Cell Mol. Biol. 13:1995;7-16
130. Escudier B., Le Chevalier T., Angevin F. Gene therapy with intratumor (IT) injection of an adenovirus expressing the IL2 gene (rAd-IL2) in lung cancer: results of a phase I study. Lung Cancer. 29(Suppl. 1):2000;184. [abstract 622]
131. Hood J.D., Bednarski M., Frausto R., et al. Tumor regression by targeted gene delivery to the neovasculature. Science. 296:2002;2404-2407
132. Tortora G., Caputo R., Damiano V., et al. Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect. Clin. Cancer Res. 9:2003;866-871
133. Tortora G., Caputo R., Damiano V., et al. Combined targeted inhibition of bcl-2, bcl-XL, epidermal growth factor receptor, and protein kinase A type I causes potent antitumor, apoptotic and antiangiogenic activity. Clin. Cancer Res. 9:2003;1566-1572
134. Normanno N., Campiglio M., De Luca A., et al. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann. Oncol. 13:2002;65-72
135. Mininberg E.D., Herbst R.S., Henderson T., et al. Phase I/II study of the recombinant humanized monoclonal anti-VEGF antibody bevacizumab and the EGFR-TK inhibitor erlotinib in patients with recurrent non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 22:2003;627
136. Betensky R.A., Louis D.N., Cairncross J.G. Influence of unrecognized molecular heterogeneity on randomized clinical trials. J. Clin. Oncol. 20:2002;2495-2499
137. Ramaswamy S., Golub T.R. DNA microarrays in clinical oncology. J. Clin. Oncol. 20:2002;1932-1941